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Summary
Background Eczema and asthma are chronic diseases with onset usually before the
age of 5 years. More than 50% of individuals with eczema will develop asthma
and/or other allergic diseases. Several loss-of-function mutations in filaggrin
(FLG) have been identified in patients with eczema. However, the association of
FLG with healthcare use is unknown.
Objectives To determine whether FLG mutations are associated with increased pre-
scribing for eczema and asthma and whether increased prescribing is associated
with increased healthcare costs.
Methods A secondary analysis of BREATHE, a cross-sectional study of gene–envi-
ronment associations with asthma severity, was undertaken. BREATHE data was
collected for 1100 participants with asthma, in Tayside and Fife, Scotland during
the period 2003–2005. Through collaboration with the Health Informatics Centre
in Dundee, BREATHE was linked to accident and emergency, community pre-
scribing and Scottish morbidity records. The data linkage allowed longitudinal
exploration of associations between genetic variation and prescribing.
Results An association was found between FLG mutations and increased prescribing
for mild and moderate eczema, asthma-reliever medicine and asthma exacerba-
tions. A strong association was found between FLG mutations and prescribing of
emollients [incidence rate ratio (IRR) 219, 95% confidence interval (CI)
136–352], treatment for severe eczema (IRR 218, 95% CI 122–391) and a
combination of a long-acting b2-agonist and corticosteroids (IRR 329, 95% CI
168–643).
Conclusions The presence of FLG mutations in this cohort is associated with
increased prescribing for eczema and asthma. Randomized controlled trials are
required to determine if these individuals could benefit from management strate-
gies to reduce morbidity and treatment costs.
What’s already known about this topic?
• Defects in FLG are associated with the development of eczema in children.
• Defects in FLG are associated with severe and persistent eczema and severe asthma.
What does this study add?
• Patients with FLG mutations were dispensed more prescriptions for both eczema
and asthma and had more asthma exacerbations over a 9-year period of study.
• This translates into higher long-term costs for these patients.
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• Children and adults with FLG mutations may benefit from targeted treatment regi-
mens that could reduce morbidity and treatment costs in this subgroup.
Eczema and asthma are common chronic diseases.1,2 Eczema
affects 15–20% of schoolchildren and 2–10% of adults and
asthma affects 16–18% of the U.K. population.2–4 Almost
three-quarters of children with early-onset eczema, a severe
and persistent form of eczema, will develop asthma in later
life.5,6
Eczema and asthma result from a combination of genetic
and environmental factors and are treated by a stepwise
approach. Eczema is treated initially with emollients followed
by the addition of topical corticosteroids (TCS). The strength
of prescribed TCS increases with the severity of eczema. Anti-
histamines may be prescribed to help pruritus. Additional
treatment includes topical calcineurin inhibitors and wet
wrapping with bandages or eczema garments.7 Asthma treat-
ment follows the British Thoracic Society (BTS) guidelines,
with short-acting b2-agonists (SABA) as step one. Regular
inhaled corticosteroids (ICS) are added in children with fre-
quent SABA use (BTS step two). With increasing disease sever-
ity, long-acting b2-agonists (LABA), leukotrienes receptor
antagonists (LTRA), theophyllines and immunosuppressants
are added as subsequent steps.2,8
In the past decade, several studies9–17 have shown an asso-
ciation of FLG mutations and severe and persistent eczema,
however, the strength of the association is unclear. One study
did not find an association between the presence of FLG muta-
tions and eczema severity18 and several studies were cross-sec-
tional. Therefore, to achieve a clearer understanding of the
role of FLG mutations in eczema and asthma in childhood fur-
ther exploration of the associations of these mutations with
longitudinally measured outcomes was needed, particularly
looking at prescribing costs. Although asthma severity, mea-
sured as a higher BTS asthma treatment step or risk of asthma
exacerbations, has also been associated with FLG mutations in
individuals with and without eczema,11,16 the role of FLG
mutations on prescribing-related outcomes in childhood
asthma has not been explored.
The tracking of filaggrin-related eczema and asthma, in
comparison with filaggrin-unrelated eczema and asthma, may
reveal different long-term patterns of prescribing and other
healthcare use for the two genetically distinct forms of the dis-
eases. One measure of assessing healthcare use and medication
costs is through analysis of dispensed prescriptions.19–21 This
refers to a prescription both issued by the physician and col-
lected by the patient, from a pharmacist. Existing prescribing
databases have tracked dispensed prescriptions in Tayside for
several decades, thus providing a unique opportunity to
explore differences in prescription use according to FLG geno-
type for both eczema and asthma in BREATHE.16,22–24 The
aim of this study was to determine whether FLG mutations are
associated with increased prescribing of medication for eczema
and asthma and/or an increased number of asthma exacerba-
tions and whether this translates into different healthcare
costs.
Patients and methods
BREATHE is a cross-sectional study of gene–environment
interactions in 1100 children and adults with physician-diag-
nosed asthma aged between 2 and 22 years. Study recruitment
and initial data collection was undertaken in 2003 to 2005.
One of the genes investigated in BREATHE was FLG. Collabora-
tion with the Health Informatics Centre in Dundee, Scotland,
provided an opportunity to link all participants in BREATHE
with the Scottish morbidity records–01 database, the accident
and emergency database of Tayside and the community phar-
macy database. Through this linkage, it was possible to
explore longitudinally the variations in prescribing and other
health outcomes. Only patients with a valid community health
index number, a unique identifier similar to the National
Health Service (NHS) number in England, were included in
the cohort. All participants were followed for 9 years, from
2005 to 2013.
Four FLG polymorphisms, common in a white population
were considered: R501X (rs61816761), 2281del4
(rs41370446), S3247X (rs150597413) and R2447X
(rs138726443). Individuals (n = 23) with no signal/amplifi-
cation for any of the four FLG polymorphisms were excluded
from subsequent analysis. Each polymorphism considered had
a genotype call rate of 99% and the minor allele frequency
was greater than or equal to 1%. The Hardy–Weinberg equi-
librium was tested for each polymorphism. A deviation was
seen for R501X and S3247X; however, variants associated
with the disease are overrepresented in patients and will show
a deviance from Hardy–Weinberg equilibrium. Therefore,
these polymorphisms were not excluded from the analysis.25
For the analysis, the effect of having at least one of the four
polymorphisms was compared with the effect of having no
polymorphisms. Additional variables were determined from
the literature and included: family history of eczema and
asthma, cat ownership, age, sex and self-report of eczema.
Genotyping for the FLG polymorphisms was performed as
described in earlier publications.11,12,16
The methodology for determining prescription dispense-
ment in relation to clinical outcomes has been well-validated
in Dundee.19–21 Dispensed prescriptions were grouped into
eczema or asthma medications by a dermatologist (J.F.) and
paediatricians (K.F. and S.M.) according to the British National
Formulary guidelines and are representative of common practice
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within the U.K. The eczema-related medicines were classified
as: emollients, antihistamines and other treatments for mild,
moderate and severe eczema (Table S1; see Supporting Infor-
mation). Asthma-related prescriptions were divided into relie-
ver medicine (SABA and ipratropium bromide) and controller
medicines (ICS; LABA; a combination of LABA with ICS; long-
acting antimuscarinic (LAMA) controller and LTRA) (Table S2;
see Supporting Information). LAMA controller medicine is
used only in adults; therefore, the number of LAMA prescrip-
tions in this cohort is small. This group of medicine was not
analysed as only five individuals had LAMA controller pre-
scriptions. Asthma exacerbations were defined as asthma-
related hospital admissions and/or dispensement of a short
course of prednisolone, an oral corticosteroid usually pre-
scribed for asthma attacks.16
All statistical analysis was performed using Stata 14.0 (Stata-
Corp, College Station, TX, U.S.A.) and R 3.2.2 (R Foundation,
Vienna, Austria). The four polymorphisms were combined
into two categories: no FLG mutation vs. one or more FLG
mutations. The outcomes are the number of prescriptions dis-
pensed and asthma exacerbations per patient for each year.
The analyses regarding eczema were performed on individuals
with eczema and asthma; 530 children and adults, and the
analyses concerning asthma were performed on the entire
cohort of 978 children and adults. Negative binomial regres-
sion was used to model overdispersed (i.e. variance greater
than the mean) count outcomes. A negative binomial model
with a random effect for the patient was found to be the most
adequate to assess the association between FLG mutations and
prescribing for eczema and asthma, and with asthma exacerba-
tions. Incidence rate ratios (IRRs) were estimated for all vari-
ables. Each of the models was adjusted for age, sex, FLG status
and cat ownership. The P-values were not adjusted for multi-
ple testing as, despite reducing the risk of a type I error, this
increases the type II error.26,27 Instead, we focused on the
effect estimation of the association and its magnitude. An IRR
between 05 and 2 (excluding 1, no association) was defined
as a weak-to-moderate association, whereas, an IRR outside
these limits was considered a strong association.28,29
A cost analysis was performed on the prescribed medica-
tion based on Scottish (Information Service Division) prices
obtained from 2005 to 2013, expressed in 2014 pounds ster-
ling (see Tables S1 and S2 in the Supporting Information for
the range of prices for each pharmaceutical compound. Varia-
tions in price for a pharmaceutical compound were because
of different strengths and different formulation codes). Costs
for hospital admission were only obtained for Fife in 2015
(in the case of hospitalizations, the daily cost of inpatient
admission for paediatrics was £477 and the price of a day
case was £77. The daily cost of an attendance at the accident
and emergency department was £1070). We estimated the
prices would not vary significantly over the 9-year period
and between Fife and Tayside. All individuals were included
in the analysis, regardless of having dispensed a prescription
or not, to get an estimate of the cost of eczema for anyone
with the condition. To estimate the difference in costs for
asthma exacerbation, only individuals admitted to the hospital
with an asthma-related event as the main cause were consid-
ered. A bias-corrected and accelerated (BCa) bootstrapped t-
test was used to obtain confidence intervals (CI) for the
means.30 The BREATHE study and subsequent analyses have
approval from the Tayside Medical Research and Ethics Com-
mittee.
Results
Of the 1100 children and young adults in the dataset, 23 indi-
viduals were excluded as they lacked genotyping information
and 99 individuals were excluded because of missing clinical
information. The final dataset included 978 children and
adults with asthma. Participants were asked whether they, or
their child, had eczema, at study collection, and 530 (542%)
answered positively.
Of the 530 children with eczema and asthma, 43 (81%)
had not had an eczema-related prescription during the 9-year
period. We anticipated that some children reported not to
have eczema would develop eczema over the follow-up.
Analysis of prescriptions dispensed over the 9-year period
revealed two individuals with severe eczema who were prob-
ably misclassified and 12 who probably had a mild form of
eczema. Table 1 presents the characteristics of the study pop-
ulation.
Table 1 Characteristics of BREATHE study participants
Variable
BREATHE
(n = 978)
Patients with
eczema (n = 530)
Patients without
eczema (n = 448)
Age, at data collection, median (IQR) 10 (7–13) 10 (7–13) 10 (7–13)
Male patients 584 (597) 323 (609) 261 (582)
Individuals with FLG mutations 163 (167) 119 (224) 44 (98)
Cat owners 253 (259) 124 (234) 129 (288)
Children and young adults with parental
family members with eczema
202 (206) 137 (258) 65 (145)
Children and young adults with parental
and nonparental family members with asthma
607 (621) 338 (638) 269 (60)
Values are n (%) unless otherwise stated. IQR, interquartile range.
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Eczema-related prescriptions
Overall, FLG mutations were associated with the number of
eczema-related prescriptions during the follow-up (IRR 155,
95% CI 111–216) (Table 2). Age and sex were also related
to the number of eczema-related prescriptions; these associa-
tions were weak-to-moderate (Table 2). A stronger association
was found between the presence of FLG mutations and the
number of emollients dispensed (IRR 219, 95% CI 136–
352), and the presence of FLG mutations and the number of
prescriptions dispensed for severe eczema (IRR 218, 95% CI
122–391) (Table 2). A weak-to-moderate association was
found between the presence of FLG mutations and the number
of mild and moderate prescriptions dispensed for eczema
(Table 2). There was no evidence of an association between
the presence of FLG mutations and the number of antihistami-
nes dispensed (Table 2).
Asthma-related prescribing
The presence of FLG mutations was associated with the num-
ber of all asthma-related prescriptions dispensed (IRR 130,
95% CI 107–158) (Table S3; see Supporting Information). A
strong association was found between the presence of FLG
mutations and the number of LABA with ICS dispensed (IRR
329, 95% CI 168–643) (Table S3). A weak-to-moderate
association was also found between age and the number of
asthma-related prescriptions (Table S3). Similarly, a weak-to-
moderate association was found between the number of
relievers dispensed and the presence of FLG mutations
(Table 3). There was no evidence of an association between
the presence of FLG mutations and the number of ICS, inhaled
LABA and oral LTRA dispensed (Table S3).
Asthma exacerbations
Overall, children and adults with FLG mutations had signifi-
cantly more asthma exacerbations than children and adults
without FLG mutations (IRR 176, 95% CI 127–245)
Table 2 Association between the number of eczema-related
prescriptions and FLG in individuals with eczema and asthma
Variables
Incidence
rate ratio
95%
confidence
interval P-value
All eczema-related prescriptions
Study year 100 (096–105) 087
FLG (no vs. yes) 155 (111–216) 001
Age (years) 096 (093–099) 002
Sex (male vs. female patients) 152 (114–203) 0004
Cat (no vs. yes) 085 (061–120) 036
Antihistamine prescriptions
Study year 097 (092–103) 034
FLG (no vs. yes) 123 (082–185) 032
Age (years) 096 (092–100) 006
Sex (male vs. female patients) 146 (103–206) 003
Cat (no vs. yes) 078 (052–117) 022
Emollient prescriptions
Study year 100 (093–107) 095
FLG (no vs. yes) 219 (136–352) 0001
Age (years) 090 (086–095) < 0001
Sex (male vs. female patients) 174 (115–263) 0009
Cat (no vs. yes) 076 (047–123) 027
Prescriptions for mild eczema
Study year 093 (087–099) 003
FLG (no vs. yes) 159 (103–245) 004
Age (years) 093 (088–097) 0001
Sex (male vs. female patients) 198 (136–288) < 0001
Cat (no vs. yes) 097 (063–151) 091
Prescriptions for moderate eczema
Study year 093 (087–100) 006
FLG (no vs. yes) 186 (117–296) 0008
Age (years) 099 (095–105) 085
Sex (male vs. female patients) 187 (124–281) 0003
Cat (no vs. yes) 106 (066–171) 080
Prescriptions for severe eczema
Study year 098 (090–107) 063
FLG (no vs. yes) 218 (122–391) 0009
Age (years) 101 (095–107) 088
Sex (male vs. female patients) 139 (084–232) 020
Cat (no vs. yes) 142 (080–255) 023
Table 3 Difference in cost between children and adults with and
without FLG mutations, between 2005 and 2013a
Variables
Difference
in means, £
Bias-corrected and
accelerated 95% CI, £
All eczema-related
prescriptions
9456 (1705 to 20876)
Antihistamine prescriptions 1084 (379 to 2957)
Emollient prescriptions 2892 (047 to 6921)
Prescriptions for
mild eczema
633 (414 to 2096)
Prescriptions for
moderate eczema
1294 (005 to 3932)
Prescriptions for
severe eczema
3553 (630 to 8278)
All asthma-related
prescriptions
48767 (16874 to 83607)
Reliever prescriptions 7906 (3263 to 16091)
Corticosteroid prescriptions 1181 (3682 to 2189)
Long-acting b2-agonist
prescriptions
1700 (3999 to 4085)
Long-acting b2-agonist
with corticosteroid
prescriptions
29521 (10776 to 49145)
Leukotriene prescriptions 12655 (1369 to 24644)
Asthma exacerbations 48511 (5513 to 150265)
Total cost for patients with
eczema and asthma
118223 (25782 to 301216)
Total cost for patients
with asthma
107563 (33547 to 236559)
aFigures prefixed with a minus sign indicate that the costs in
children with FLG mutations are less than in children without
these mutations. CI, confidence interval.
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(Table S4; see Supporting Information). Age and cat owner-
ship were also associated with the number of asthma exacer-
bations; these associations were weak-to-moderate.
Healthcare system costing
Over the 9-year period, prescription costs for eczema in children
and adults with FLGmutations were £95 (BCa CI £17–209) more
than children and adults without FLG mutations. Over 9 years,
the mean cost of eczema-related prescriptions for individuals
with FLG mutations was £244 compared with £150 of eczema-
related prescriptions for those without FLG mutations. There was
no evidence of a difference in costs for antihistamines and for
mild eczema according to FLG genotype but a significant differ-
ence was found between FLG status for the cost of emollients and
prescribing for moderate and severe eczema (Table 3).
Over the 9-year period, prescription costs for asthma in
children and adults with FLG mutations were £488 (BCa CI
£169–836) more than children and adults without FLG muta-
tions. Over 9 years, the mean cost of asthma-related prescrip-
tions for individuals with FLG mutations was £1443 compared
with £955 for those without FLG mutations. There was no evi-
dence of a difference in costs for ICS and LABA according to
FLG genotype but a significant difference was found between
FLG status for the cost of prescribing of relievers, a combina-
tion of LABA with ICS and LTRA (Table 3). Over the 9-year
period, costs for asthma exacerbation in children and adults
with FLG mutations were £485 (BCa CI £55–1503) more than
children and adults without FLG mutations. Over 9 years, the
mean cost of asthma exacerbations for individuals with FLG
mutations was £1013 compared with £528 for those without
FLG mutations (Table 3).
Regarding children and adults with eczema and asthma, there
was a £1182 (BCa CI £258–3012) difference in costs between
individuals with and without FLG mutations (Table 3). The fig-
ure is similar considering individuals with asthma, regardless of
having eczema. The costs for children and adults with FLG
mutations and asthma were £1076 (BCa CI £335–2366) more
than those for children and adults without FLG mutations
(Table 3). See Tables S5 and S6 in the Supporting Information
for differences in cost for eczema and asthma prescriptions,
respectively, between children and adults with and without FLG
mutations for each year of the study period.
Discussion
This study shows that over a 9-year period, FLG mutations
played a role in eczema and asthma phenotype, prescribing
patterns and healthcare costs for both eczema and asthma.
A strong association between FLG mutations and the prescrib-
ing of emollients and treatment for severe eczema has been
demonstrated. A good epidermal barrier prevents water loss and
the penetration of allergens. However, FLG mutations lead to an
impaired epidermal barrier and studies have shown that indi-
viduals with FLG mutations have higher transepidermal water
loss, and clinically drier and thicker skin than individuals
without such mutations.31,32 This may explain the higher num-
ber of emollients dispensed by adults and children with FLG
mutations in comparison with those without such mutations.
The presence of FLG mutations has also been associated with a
more severe form of eczema,9–17 which is concordant with our
observations that children and adults with FLG mutations dis-
pensed more prescriptions related to severe eczema than indi-
viduals with eczema but without such mutations.
Our study also found an association between the presence
of FLG mutations and an increase in the prescriptions of LABA
with ICS. A weak-to-moderate association was found between
FLG and asthma exacerbations. We have previously reported
an association between the presence of FLG mutations and a
carer- or patient-reported, cross-sectional assessment of asthma
severity.23 Through the relative control of skin-barrier func-
tion, the presence of FLG mutations could represent a unifying
mechanism linking eczema and asthma phenotype.
Regarding costs to the NHS, children and adults with FLG
mutations incurred higher costs due to a higher number of dis-
pensed prescriptions for eczema and asthma, and asthma exacer-
bations, than children and adults without FLG mutations. It is
important to note that physicians were unaware of FLG status
and prescribed medicine based solely on clinical appearance and
symptoms. Over a 9-year period, the healthcare system spent
£1000 more to treat individuals with asthma with FLG muta-
tions than individuals with asthma without FLG mutations.
Our cost analysis was a conservative estimate as it was based
on medication and hospital admission costs only; other
resource use was considered out of the scope of this analysis.
Nevertheless, one can estimate the extra cost of treating indi-
viduals with FLG mutations for the NHS. In 2016, Scotland’s
population was estimated at 53 million, with 106 births per
1000 people. In 2015, a study in Aberdeen estimated eczema
prevalence at 29% and asthma prevalence at 19%.33 Assuming
that the prevalence of asthma and eczema in Aberdeen can be
generalized to Scotland, one can extrapolate that of the
56 180 children born in 2016, around 16 292 may develop
eczema, and 10 674 may develop asthma. Assuming that 40%
of children with eczema will also develop asthma, around
6517 children born in 2016 could eventually have both dis-
eases. Table 1 shows the proportion of children and adults
with asthma and with FLG mutations (167%), which corre-
spond to 1783 children with asthma and FLG mutations. Using
that data and considering the prescribing cost for eczema,
asthma and hospitalizations one can extrapolate that over a
9-year period the NHS may spend approximately an additional
£1 918 000 (estimates vary between £598 000 and
£4 218 000) treating children with asthma and FLG mutations
than children with asthma without FLG mutations.
Our cost analysis also generated wide CIs, bringing more
uncertainty to our results, and indicating the considerable vari-
ability of costs among patients. Our collaboration with the
Health Informatics Centre in Dundee allowed us to analyse the
data longitudinally, over a 9-year period. This relatively long
period of follow-up was more representative of the natural his-
tory of eczema and asthma in childhood and young adulthood.
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A potential weakness of our study is that our definition of
eczema relies on carer or patient report and may, on occasion,
be subjective. Thus, although parents have positively identified
their children as having eczema, 43 children did not have any
eczema-related prescriptions over the 9-year period. These
children could have had very mild eczema, could have out-
grown their eczema, been misclassified or moved outside Scot-
land, which may have underestimated the real cost of
individuals with eczema. Another limitation of our study is
that it is impossible to be certain that the prescriptions listed in
Table S1 (see Supporting Information) were for eczema and
related conditions. As we have mentioned in the legends for
Tables S1 and S2, these medicines are eczema- and asthma-
related, although some medicines, such as antihistamines,
might also be used for related allergic conditions. However,
we feel this is a reasonable assumption, as conditions other
than eczema that are managed with topical steroids are very
uncommon in children (for example, the prevalence of psoria-
sis in children is around 1%).34 In addition, as part of the
research protocol, the children and/or their carers have already
stated whether or not the child participant had eczema.
We wished to replicate our results in independent cohorts
within the international Pharmacogenomics in Childhood
Asthma consortium,35 which has genotyped data on 14 619
children and young adults with asthma from 11 different
countries. However, from a worldwide search, we were
unable to find any cohorts of atopic children genotyped for
FLG with longitudinal pharmacy data.
The greater morbidity and the greater costs for filaggrin-
related eczema and asthma in comparison with filaggrin-unre-
lated eczema and asthma could represent a unique opportunity
in common chronic diseases such as asthma and eczema for
developing targeted management strategies that could influence
disease burden in the community. A randomized controlled
trial (RCT)36 and a pilot study37 have found a delay in the
onset of eczema in neonates exposed to daily emollients during
an 8- and 6-month period, respectively. It may thus be possible
to genotype children for FLG mutations at, or soon after, birth
and intervene with regular, intensive use of emollients. These
results indicate that targeted genotyping in early childhood, if
successful in developing interventions that even marginally
reduce disease burden, could offer many decades of lower pre-
scribing and reduced hospital costs, thus offering a potential
solution to spiralling healthcare expenditure in organizations
such as the NHS. Thus, while precision medicine could con-
tribute to the development of novel medication, a major bene-
fit in common chronic disease could be the more rational use
of currently available therapies, such as daily use of emollients
since birth, leading to major cost savings for healthcare systems
and improvements in disease control and quality of life.
There was a need to demonstrate the effect of FLG mutations
on healthcare costs, as healthcare costs are of major importance
to the NHS and any effect on the increase of such costs needed to
be either demonstrated or refuted with clarity before proceeding
with larger studies that test interventions aiming to lower such
costs. It is possible to progress with such studies now that the
effect of FLG mutations on specific healthcare outcomes has been
demonstrated. Thus, a future RCT in children with filaggrin-
related eczema could test the benefit from more intensive use of
emollients on outcomes such as prescribing and other costs for
moderate-to-severe eczema measured over some years.
It will be particularly interesting to test the hypothesis that
enhanced skin-barrier function, secondary to increased emol-
lient use, reduces hospital costs from asthma exacerbations and
community prescribing costs, thus testing novel treatment
strategies that are underpinned by the pathological relationships
between FLG defects, deficient skin-barrier function and asthma
that we have described in this article and in earlier publica-
tions.23,38 The challenge lies in translating results such as ours
into large-scale RCTs of targeted interventions in common
chronic diseases with robust mechanisms for prospectively
measuring treatment costs in the community. Community
pharmacy databases that longitudinally track prescription
encashment and hospital morbidity records that longitudinally
track clinical outcomes may be useful in cost-effectively mea-
suring such outcomes. This is particularly relevant in the con-
text of the role of FLG mutations in eczema and asthma, as
there is existing evidence that altered epidermal permeability,
the primary functional defect resulting from these mutations,
can be corrected during early life by the use of emollients.36,37
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